<DOC>
	<DOCNO>NCT01215175</DOCNO>
	<brief_summary>This study conduct evaluate safety , tolerability , immunogenicity 15-valent Pneumococcal conjugate vaccine ( V114 ) compare Prevnar™ healthy adult toddler .</brief_summary>
	<brief_title>Safety Tolerability Study Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ ( V114-001 EXT1 ) ( COMPLETED )</brief_title>
	<detailed_description>The study extend obtain additional serum adult participant support development , validation , performance anti-pneumococcal antibody assay .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion criterion : Adult Stage : Adults ≥18 45 year age good health . Signed date informed consent prior receipt vaccine . Afebrile ( &lt; 100.4°F [ &lt; 38.0°C ] oral equivalent ) day vaccination . Participant able read , understand , complete study questionnaire ( i.e. , Vaccine Report Card ) . Participant able attend schedule visit comply study procedure . Participant access telephone . Females must negative urine pregnancy test . Toddler Stage : Healthy toddler , 1215 month age previously complete document full 3 dose infant series Prevnar™ 2 , 4 , 6 month age . Participant 's parent/legal guardian understands study procedure , alternate treatment available risk involve study , voluntarily agree participate give write informed consent . Afebrile , rectal temperature &lt; 38.1°C ( &lt; 100.5°F ) axillary temperature &lt; 37.8°C ( &lt; 100.0°F ) day vaccination . Participant 's parent/legal guardian able read , understand , complete study questionnaire ( i.e. , Vaccination Report Card ) . Participant able attend schedule visit comply study procedure . Participant 's parent/legal guardian access telephone . Exclusion criterion : Adult Stage : Receipt pneumococcal polysaccharide vaccine time receipt polysaccharide conjugate vaccine second year life . Known hypersensitivity component pneumococcal conjugate vaccine . Known suspect immunocompromised person , include person congenital immunodeficiency , human immunodeficiency virus ( HIV ) infection , leukemia , lymphoma , Hodgkin 's disease , multiple myeloma , generalized malignancy , chronic renal failure ( recent serum creatinine value medical record ≥3 mg/dL ) , nephritic syndrome , condition associate immunosuppression organ bone marrow transplant . Functional anatomic asplenia . History autoimmune disease include multiple sclerosis ( MS ) , systemic lupus , polymyositis , inclusion body myositis , dermatomyositis , Hashimoto 's thyroiditis , Sjogren 's syndrome , rheumatoid arthritis , autoimmune disorder . History chronic fatigue syndrome . Known neurologic cognitive behavioral disorder include multiple sclerosis ( MS ) , MSlike disease , encephalitis/myelitis , acute disseminate encephalomyelitis ( ADEM ) , pervasive developmental disorder , related disorder . Participant coagulation disorder contraindicate IM vaccination . Use immunosuppressive therapy ( Note : topical inhaled/nebulized steroid permit ) . Participants corticosteroid exclude receive expect receive , period 30 day prior Visit 1 Visit 2 , systemic dos great required physiological replacement , i.e. , &gt; 5 mg prednisone ( equivalent ) daily &gt; 2 week . Excluded immunosuppressive therapy also include chemotherapeutic agent use treat cancer condition , treatment associate organ bone marrow transplantation , autoimmune disease . Any underlying illness would complicate evaluation completion study . Any licensed nonlive virus vaccine administer within 14 day prior receipt study vaccine schedule receive license vaccine within 30 day follow receipt study vaccine . ( Exception : Inactivated influenza vaccine may administer study , must give least 7 day prior receipt study vaccine least 15 day receipt study vaccine . ) Participant receive licensed live virus vaccine within 30 day prior receipt study vaccine schedule receive vaccination license live virus vaccine within 30 day receipt study vaccine . Participant receive diphtheria toxoid within 6 month prior receipt study vaccine . Prior receipt blood transfusion blood product include immune globulin administer within 6 month receipt study vaccine . Investigational drug vaccine receive within 2 month receipt study vaccine . Participation another clinical study within 42 day begin anytime duration current clinical study . Recent hospitalization acute illness within 3 month receipt study vaccine . History invasive pneumococcal disease ( positive blood culture , positive cerebrospinal fluid culture , sterile site ) know history culture positive pneumococcal disease . History febrile illness ( ≥100.40 F [ ≥38.00 C ] oral equivalent ) occur within 72 hour receipt study vaccine . Participant pregnant breastfeeding expect conceive within project duration study . Female participant reproductive potential must use 2 acceptable method birth control 2 week prior enrollment , agree use 2 acceptable method birth control 1 month vaccination . ( Acceptable method birth control include use hormonal contraceptive , intrauterine device ( IUD ) , diaphragm spermicide , contraceptive sponge , tubal ligation , condom , abstinence ) . Any participant adequately follow safety accord protocol plan . Participant unlikely adhere study procedure , keep appointment , plan relocate study . Any reason opinion investigator may interfere evaluation require study . Toddler Stage : Have receive le full 3dose infant series Prevnar™ 3rd dose less 2 month study vaccine . Known hypersensitivity component pneumococcal conjugate vaccine . Known suspected impairment immunological function . Participant history congenital acquire immunodeficiency ( e.g. , splenomegaly ) . Participant his/her mother document HIV infection . Functional anatomic asplenia . History autoimmune disease include multiple sclerosis ( MS ) , systemic lupus , polymyositis , inclusion body myositis , dermatomyositis , Hashimoto 's thyroiditis , Sjogren 's syndrome , rheumatoid arthritis , autoimmune disorder . Known neurologic cognitive behavioral disorder include multiple sclerosis ( MS ) , MSlike disease , encephalitis/myelitis , acute disseminate encephalomyelitis , pervasive developmental disorder , related disorder . Receipt intramuscular , oral , intravenous corticosteroid treatment within 2 week prior vaccination . ( Note : Toddlers topical inhaled/nebulized steroid may participate study . ) Use systemic steroid permit participant receiving le 2 mg/kg per day prednisone ( equivalent ) , less 20 mg/d weigh 10 kg otherwise immunocompromised . Participant receive licensed nonlive vaccine administer within 14 day receipt study vaccine . Participant receive licensed live virus vaccine within 30 day prior receipt study vaccine ( Exception : Influenza virus vaccine give accord recommend guideline within 7 day receive study vaccine ) . Prior receipt blood transfusion blood product , include immunoglobulin . Investigational drug vaccine receive within 2 month receipt study vaccine . Participation another clinical study within 42 day begin anytime duration current clinical study . History invasive pneumococcal disease ( positive blood culture , positive cerebrospinal fluid culture , sterile site ) know history culture positive pneumococcal disease . A recent ( &lt; 72 hour ) febrile illness ( rectal temperature ≥38.1°C [ ≥100.5°F ] ) occur within 48 hour receipt study vaccine . History failure thrive . Participant coagulation disorder contraindicate IM vaccination . Participant his/her mother document hepatitis B surface antigenpositive . Any toddler adequately follow safety accord protocol plan . Participant 's parent/legal guardian unlikely adhere study procedure , keep appointment , plan relocate study . Any reason opinion investigator may interfere evaluation require study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pneumococcal disease</keyword>
</DOC>